Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent<i>Mycobacterium tuberculosis</i>Infection

Borisov, Andrey S.; Morris, Sapna Bamrah; Njie, Gibril J.; Winston, Carla A.; Burton, Deron C.; Goldberg, Stefan; Woodruff, Rachel Yelk; Allen, Leeanna; LoBue, Philip; Vernon, Andrew

doi:10.15585/mmwr.mm6725a5

Cited by 93 publications

(53 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unlike DS-TB treatment guidelines, LTBI treatment guidelines have changed in the last decade. The biggest change was the introduction of isoniazid/rifapentine once weekly for 12 weeks as a successful LTBI treatment regimen 414243. In addition, rifampin dosed daily for four months was confirmed to be as effective as isoniazid for nine months but with better treatment completion rates and fewer side effects 44…”

Section: Preventive Tb Treatmentmentioning

confidence: 99%

Current and future treatments for tuberculosis

Lee

Xie

Barry

et al. 2020

BMJ

View full text Add to dashboard Cite

Guidelines on the treatment of tuberculosis (TB) have essentially remained the same for the past 35 years, but are now starting to change. Ongoing clinical trials will hopefully transform the landscape for treatment of drug sensitive TB, drug resistant TB, and latent TB infection. Multiple trials are evaluating novel agents, repurposed agents, adjunctive host directed therapies, and novel treatment strategies that will increase the probability of success of future clinical trials. Guidelines for HIV-TB co-infection treatment continue to be updated and drug resistance testing has been revolutionized in recent years with the shift from phenotypic to genotypic testing and the concomitant increased speed of results. These coming changes are long overdue and are sorely needed to address the vast disparities in global TB incidence rates. TB is currently the leading cause of death globally from a single infectious agent, but the work of many researchers and the contributions of many patients in clinical trials will reduce the substantial global morbidity and mortality of the disease.

show abstract

Section: Preventive Tb Treatmentmentioning

confidence: 99%

Current and future treatments for tuberculosis

Lee

Xie

Barry

et al. 2020

BMJ

View full text Add to dashboard Cite

show abstract

“…Finally, treatment of latent TB infection is critical to the control and elimination of TB infection. It is now easier to treat latent TB with once-weekly isoniazid and rifapentine for 12 weeks, preferably using directly observed administration of the medications [34].…”

Section: Measles Infectionsmentioning

confidence: 99%

“…In addition, Enteropathogenic Escherichia coli (EPEC), Vibrio cholerae, Salmonellla spp., and Campylobacter spp. as well as three parasites: Cryptosporidium spp., Entamoeba histolytica, and Giardia lamblia are also on some lists of non-viral pathogens [34] (these latter three will not be further discussed in detail). There is a concern that current interventions of viral enteritis (oral rehydration, continued feeding, and Zinc) will not be effective in treating disease caused by parasitic pathogens [38].…”

Section: Bacterial Enteric Infectionsmentioning

confidence: 99%

Infectious diseases as a cause of global childhood mortality and morbidity: Progress in recognition, prevention, and treatment

Frenkel¹

2018

apr

View full text Add to dashboard Cite

Child mortality and morbidity are far too high with almost 1% of all children around the world dying each year! Children living in underdeveloped countries (also referred to as "low-income") and in those areas where crime and military actions are part of everyday life, come under increased threat from disease, starvation, trauma, and death. Infectious diseases are responsible for more than half of childhood deaths and an even greater level of morbidity. This article will review deaths in children, generally in those less than 5 years of age, from pneumonia and other respiratory infections (including bacterial pneumonia, pertussis, viral pneumonia respiratory syncytial virus (RSV), measles, and influenza, tuberculosis (TB), bacterial and viral enteric disease (including enterotoxic (ETEC) and enteropathogenic E. coli (EPEC), Shigella, cholera, infections, rotavirus norovirus, and malaria. Factors influencing disease epidemiology and mortality especially in underdeveloped countries will be noted. Much progress has been made in decreasing infectious disease morbidity and mortality during the last few decades, but much more progress can and should be made. The role of decreasing air pollution, improving sanitation, nutrition, mosquito control, immunization rates, and use of antimicrobial agents will be discussed.

show abstract

“…About 5% to 15% of those with LTBI will develop active TB during their lifetime [5]. To prevent active TB from developing, individuals with LTBI can receive treatment, which is less intensive than treatment for active TB [6]. However, it is not recommended to treat everyone with LTBI to avoid problems of drug resistance, particularly multi-drug-resistant strains.…”

Section: Tuberculosis (Tb) Is a Bacterial Infection Caused Bymentioning

confidence: 99%

Assessment of an ultra-sensitive IFNγ immunoassay prototype for latent tuberculosis diagnosis

Salah¹,

Dorgham²,

Lesénéchal³

et al. 2018

European Cytokine Network

View full text Add to dashboard Cite

Worldwide there are about 1.7 billion individuals with latent tuberculosis infection (LTBI) and only 5% to 15% will develop active tuberculosis (TB). It is recommended to treat only those most at risk of developing active TB to avoid problems of drug resistance. LTBI diagnosis involves reviewing the individual's medical history, physical examination, and biological tests. Interferon gamma release assays (IGRA) can yield "undeterminate" or "uncertain" results, which makes clinical management decisions difficult. We assessed an ultra-sensitive immunoassay prototype based on single molecule array (SiMoA) technology to evaluate its overall performance, and in particular, its performance for indeterminate and uncertain positive or negative samples, as classified by the results from the current ELISA technique used for IFN␥ quantification. We analyzed samples from hospitalized or consulting patients and healthcare workers from three hospitals in Paris, previously classified as negative (n = 30), positive (n = 35), uncertain negative (n = 25), uncertain positive (n = 31), or indeterminate (n = 30). We observed that with the SiMoA assay 83.3% of the indeterminate samples became interpretable and could be classified as negative, whereas 74% of uncertain positive samples were classified as positive. Most uncertain negative samples (72%) were reclassified as uncertain positive (68%) or positive (4%). The results suggest that the ultra-sensitive SiMoA IFN␥ assay could represent a useful tool for the identification of true positive and negative samples among those giving indeterminate or uncertain results with the TB IGRA assay currently used.

show abstract

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat LatentMycobacterium tuberculosisInfection

Cited by 93 publications

References 9 publications

Current and future treatments for tuberculosis

Current and future treatments for tuberculosis

Infectious diseases as a cause of global childhood mortality and morbidity: Progress in recognition, prevention, and treatment

Assessment of an ultra-sensitive IFNγ immunoassay prototype for latent tuberculosis diagnosis

Contact Info

Product

Resources

About